Cita APA (7a ed.)

Canadian Agency for Drugs and Technologies in Health. (2017). Patient group input submissions Selexipag (Uptravi) for pulmonary arterial hypertension (WHO class II and III). Canadian Agency for Drugs and Technologies in Health.

Cita Chicago Style (17a ed.)

Canadian Agency for Drugs and Technologies in Health. Patient Group Input Submissions Selexipag (Uptravi) for Pulmonary Arterial Hypertension (WHO Class II and III). Ottawa (ON): Canadian Agency for Drugs and Technologies in Health, 2017.

Cita MLA (9a ed.)

Canadian Agency for Drugs and Technologies in Health. Patient Group Input Submissions Selexipag (Uptravi) for Pulmonary Arterial Hypertension (WHO Class II and III). Canadian Agency for Drugs and Technologies in Health, 2017.